Study of Amino Acid Peritoneal Dialysis Solution Use in Adults with Diabetes on Peritoneal Dialysis

What this Trial Is About

Researchers are evaluating the effects of using an amino acid 15 peritoneal dialysis solution in patients with diabetes who are undergoing peritoneal dialysis. This single-center, open, prospective, self-controlled clinical study aims to observe changes in glycosylated hemoglobin HbA1c 90 days after starting the amino acid dialysis solution. The study focuses on diabetic patients already receiving peritoneal dialysis to better understand how this treatment may influence blood sugar control and related health measures. Participants will use one bag 2 liters of amino acid 15 peritoneal dialysis solution daily after breakfast, followed by treatment with glucose peritoneal dialysis solution lactate. The study period involves monitoring patients from the start Day 0 through 90 days of treatment with this amino acid solution. This intervention is assessed without a comparison group, as each patient serves as their own control. During the study, participants will have regular assessments of blood markers including glycosylated hemoglobin, fasting blood glucose, serum albumin, hemoglobin, prealbumin, daily urine volume, ultrafiltration volume, Ktv, creatinine clearance rate Ccr, and hypoglycemic drug use. These measurements will be taken at baseline, 30 days, and 90 days to track changes over time. The total study duration for each participant is 90 days, with ongoing monitoring for safety and effectiveness of the amino acid dialysis solution.

Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients